

1 **Healthcare Consumers' Perceptions of Incentive-Linked Prescribing: A Scoping Review of**
2 **Research**

3 **Muhammad Naveed Noor^{1,2}, Haider Safdar Abbasi², Nina van Der Mark³, Zahida Azizullah²,**
4 **Janice Linton⁴, Afifah Rahman-Shepherd³, Amna Rehana Siddiqui⁵, Mishal Khan³, Rumina**
5 **Hasan², Sadia Shakoor²**

6
7 ¹Institute for Global Public Health, Department of Community Health Sciences, University of
8 Manitoba, Winnipeg, Manitoba, Canada; ²Department of Pathology and Laboratory Medicine,
9 Aga Khan University, Karachi, Pakistan; ³Department of Global Health and Development,
10 London School of Hygiene and Tropical Medicine, London, UK; ⁴Neil John Maclean Health
11 Sciences Library, University of Manitoba, Winnipeg, Manitoba, Canada; ⁵Jinnah Sindh Medical
12 University, Karachi, Pakistan.

13
14 **Correspondence: Dr Mishal Khan, mishal.khan@lshtm.ac.uk.**

15

16

17

18

19

20

21

22

23

24

25

26 **Healthcare Consumers’ Perceptions of Incentive-Linked Prescribing: A Scoping Review of** 27 **Research**

28 **Abstract**

29 Incentive-linked prescribing (ILP) is considered a controversial practice universally. If
30 incentivised, physicians may prioritise meeting pharmaceutical sales targets through
31 prescriptions, rather than considering patients' health and wellbeing. Despite the potential
32 harms of ILP to patients and important stakeholders in the healthcare system, healthcare
33 consumers (HCCs) which include patients and the general public often have far less awareness
34 about the practice of pharmaceutical incentivisation of physicians. We conducted a scoping
35 review to explore what existing research says about HCCs’ perceptions of the financial
36 relationship between physicians and pharmaceutical companies. To conduct this scoping
37 review, we followed Arksey and O'Malley’s five-stage framework: identifying research
38 questions, identifying relevant studies, selecting eligible studies, data charting, and collating,
39 summarising, and reporting results. We also used the Preferred Reporting Items for Systematic
40 Reviews and Meta-Analyses’ extension for scoping reviews (PRISMA-ScR), as a guide to organise
41 the information in this review. Quantitative and qualitative studies with patients and the
42 general public, published in the English language were identified through searches of Scopus,
43 Medline (OVID), EMBASE (OVID), and Google Scholar. Three themes emerged through the
44 analysis of the 13 eligible studies: understanding of incentivisation, perceptions of hazards
45 linked to ILP, and HCCs’ suggestions to address it. We found documentation that HCCs exhibited
46 a range of knowledge from good to insufficient about the pharmaceutical incentivisation of
47 physicians. HCCs perceived several hazards linked to ILP such as a lack of trust in physicians and

48 the healthcare system, the prescribing of unnecessary medications, and the negative effect on
49 physicians' reputations in society. In addition to strong regulatory controls, it is critical that
50 physicians self-regulate their behaviour, and publicly disclose if they have any financial ties with
51 pharmaceutical companies. Doing so can contribute to trust between patients and physicians,
52 an important part of patient-focused care and a contributor to user confidence in the wider
53 health system.

54 Keywords: Patients; Physicians; Pharmaceutical Industry; Incentives; Prescribing; Healthcare

55 **Introduction**

56 The relationship between physicians, the pharmaceutical industry, and patients could be
57 better understood in terms of a triangle; while each of them is positioned at unique vertices,
58 they are always connected through a relationship of exchange. Physicians are qualified to
59 practice medicine and conduct the diagnosis and treatment of illnesses; the pharmaceutical
60 industry manufactures drugs prescribed by physicians to manage/treat illnesses; and patients
61 are the 'end-users' who place their trust in physicians to improve their health. Unethical drug
62 promotion is a widely used practice by pharmaceutical companies, in which sales
63 representatives offer incentives to physicians in exchange for prescriptions of their companies'
64 drugs. This practice is thought to distort physicians' prescribing behaviour. (1-3) When
65 incentivised, physicians may choose to prescribe drugs, which are either unnecessary or
66 expensive (4). Consequently, incentive-linked prescribing (ILP) may negatively affect patients'
67 health or exacerbate their financial difficulty. (4-6)

68 In recent years, there has been a steady stream of published studies about ILP from
69 different parts of the world (5-8). However, most of this work is based on research with

70 physicians, the pharmaceutical industry, and other relevant stakeholders (i.e., regulators or
71 nongovernmental organisations) rather than documenting the perspectives of HCCs. This
72 research is important and adds to our understanding of the mechanisms through which ILP
73 happens and the factors that mediate this process. Because patients are also important
74 stakeholders in the healthcare system and perhaps the most at risk of suffering the financial or
75 physical consequences of ILP, it is critical to take their perspectives into account. Researchers
76 from various countries have attempted to explore the perceptions of patients and the general
77 public regarding the financial relationship between physicians and the pharmaceutical industry.
78 We suggest that both population groups may be better described as healthcare consumers
79 (HCCs), due to the experience of their consumption of healthcare services as well as
80 pharmaceutical products.

81 Trust in physicians is considered a key strength of any healthcare system. (9) In settings,
82 where HCCs lack trust in physicians, a decreased adherence to the treatment recommended by
83 physicians has been noted. (10) There is strong evidence that ILP happens at a large scale
84 specifically in low- and middle-income countries (LMICs). (4, 11-13) Nevertheless, little is known
85 about what views HCCs hold regarding the financial relationship between physicians and
86 pharmaceutical companies, the extent to which it can affect their trust in physicians, and what
87 they think about how incentivization of physicians by pharmaceutical companies may affect
88 them. Understanding HCCs' views is critical for informing policies and practices around ethical
89 pharmaceutical marketing and prescribing, towards sustaining patients' trust in healthcare
90 professionals and the healthcare sector more broadly.

91 The most recent systematic review in this field was conducted in 2016, with a focus on
92 the knowledge, beliefs and attitudes of HCCs around interactions of physicians with
93 pharmaceutical and device industries offering a quantitative analysis of the acceptability of
94 physicians' financial engagement with these industries. (14) Our scoping review provides a
95 detailed narrative analysis of HCCs' perspectives of pharmaceutical incentivisation to physicians
96 and significantly complements previous knowledge synthesis in the field. Our analysis
97 specifically offers several important messages for physicians and other health professionals
98 worldwide, orienting their attention to the level of awareness amongst HCCs about unethical
99 exchanges taking place in clinical settings, and how this may affect physician reputation in
100 society. Since little is known about the level of HCCs' awareness of ILP and how this practice has
101 been perceived by and has affected them, a scoping review of the existing research is essential
102 to inform policy and practice globally, regionally and in individual clinical settings.

103 **Research objective and questions**

104 The overarching objective of the review is to present an analysis of the published evidence on
105 HCC's perspectives regarding pharmaceutical incentivisation to physicians. Our main question
106 was what does existing research say about HCCs' perceptions of the relationship between
107 physicians and pharmaceutical companies? The specific questions that we aimed to answer
108 through this review included:

- 109 1. How aware are HCCs about ILP and what information do they have regarding the
110 incentive types given to physicians?
- 111 2. What are HCCs' perceptions of the effects of pharmaceutical incentivisation of
112 physicians in exchange for prescriptions?

113 3. What actions do HCCs think are necessary to address the pharmaceutical incentivization
114 of physicians?

115 **Materials and methods**

116 A protocol to conduct this scoping review was registered with Open Science Framework. (15)

117 We used a five-stage framework developed by Arksey and O'Malley. These stages include

118 identifying research questions, identifying relevant studies, selecting eligible studies, data

119 charting, and collating, summarising, and reporting results. (16) To present information in this

120 article, we employed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses'

121 extension for scoping reviews (PRISMA-ScR), as a guide. (17) The inclusion and exclusion

122 criteria for studies in this review are given in Box 1.

123 Stage 1 involved designing the search strategy and crafting research questions. Based on

Box 1: Inclusion and exclusion criteria of studies

Inclusion criteria

- Studies with inpatients, outpatients, and the general public about their perspectives/opinions/views on the financial/material relationship between physicians and pharmaceutical companies.
- Empirical studies employing quantitative and qualitative methods.
- Journal articles published between 2003 and 2023.
- Studies only published in the English language.

Exclusion criteria

- Books, book chapters, editorials, opinions, and review articles.
- Grey literature such as information briefs, organizational reports, and theses.
- Studies seeking to understand the opinions of regulators and healthcare professionals such as physicians and pharmaceutical professionals.
- Studies published before 2003 to specifically look for published work within the last 20 years.

124 our preliminary search through Google Scholar, we found that a limited number of studies on

125 this issue were available. Thus, our main question was what existing studies say about how

126 HCCs perceived pharmaceutical incentivisation to physicians. As we performed a preliminary
127 scan of the literature, we noticed many examples of HCCs' perceptions of pharmaceutical
128 incentivisation to physicians, leading to our next question of how HCCs understand the
129 incentivisation practice with respect to different countries. It is usual for researchers to propose
130 potential actions for future research, policy, and practice. However, we were interested in
131 exploring what ways HCCs think of addressing ILP.

132 At stage 2, we began our formal search of the following databases: Scopus, Medline
133 (OVID) and EMBASE (OVID). This search was conducted by an experienced academic health
134 sciences liaison librarian [JL] on September 12, 2023, using a combination of keywords and
135 subject headings (see Box 2). Limits were applied to retrieve results of citations to articles
136 published in English from 2003 to the date of the search. The earliest study matching our
137 criteria was in 2006. Additional searching was carried out via Google Scholar (first 10 pages) [by
138 MNN] examining documents related to the key publications identified in the database searches,
139 but we were unable to find any new studies.

140 At stage 3, from each database, we generated RIS files containing citations that were
141 imported into Covidence – a website-based software to manage and carry out research
142 reviews. (18) To identify the relevant studies, search results from Scopus, Medline (OVID) and
143 EMBASE (OVID) were imported into Covidence. (18) Then, duplicates were identified and
144 removed first using the automated tool in Covidence, and then manually by the research team.
145 Title and abstract screening of the remaining studies was performed by a research specialist
146 (HSA), to remove ineligible studies, following which, a full-text screening was performed by two

Box 2: Literature search strategy

Scopus (n=445)

(TITLE-ABS-KEY(physician OR physicians OR physician* OR doctor OR doctors) AND TITLE-ABS(patient OR patients) AND TITLE-ABS-KEY("pharmaceutical industry" OR "drug company" OR "drug companies" OR "drug manufactur*" OR "drug industry")) AND TITLE-ABS(financial OR graft OR influence* OR freebie* OR gift OR gifts OR monetary OR cash OR money)) AND PUBYEAR > 2002 AND PUBYEAR < 2024 AND (LIMIT-TO (DOCTYPE,"ar") OR LIMIT-TO (DOCTYPE,"re") OR LIMIT-TO (DOCTYPE,"ed")) AND (LIMIT-TO (LANGUAGE,"English"))

Medline (n=77)

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily <1946 to September 11, 2023>

1	Gift Giving/	1708	
2	Drug Industry/	35019	
3	1 and	2522	
4	patient*.ti,ab,kf.	8188156	
5	Patients/	24328	
6	public.ti,ab.	593506	
7	4 or 5 or 6	8650625	
8	1 and 2 and 7	112	
9	(comment or editorial or news or newspaper article).pt.	1696172	
10	(letter not (letter and randomized controlled trial)).pt.	1222049	
11	9 or 10	2403074	
12	8 not 11	97	
13	limit 12 to (english language and yr="2002 -Current")	77	

Embase (42)

Embase <1974 to 2023 Week 36>

1	Gift Giving/	1253	
2	Drug Industry/	92160	
3	1 and	2360	
4	patient*.ti,ab,kf.	11972863	
5	Patients/	1057052	
6	public.ti,ab.	708395	
7	4 or 5 or 6	12493306	
8	1 and 2 and 7	61	
9	limit 8 to (article or article in press or "review")	53	
10	limit 9 to (english language and yr="2002 -Current")	42	

148 team members (MNN and HSA) collaboratively, to determine the final number of eligible
149 studies for this review. The study selection process is illustrated in Figure 1.

150 **Figure 1 Caption: Flowchart of the study selection process**

151 At stage 4, the data extraction and charting were performed on a Microsoft Excel
152 Spreadsheet by three team members (HSA, ZA, and NVM). The team lead (MNN) then reviewed
153 the data extraction matrix and resolved contradictions. We first screened for and recorded
154 basic study information (year, setting, method, sample, and key findings) and HCCs'
155 characteristics (number of participants, and distribution of participants with respect to age and
156 gender).

157 Finally, at stage 5, in line with the research questions, the team lead (MNN) conceptualised
158 and reorganised various themes presented in the data matrix. The final condensed version of
159 the data matrix guided the reporting of the results.

160 **Results**

161 ***Overview of studies***

162 We identified a total of 564 references from databases such as Scopus, Medline (OVID) and
163 EMBASE (OVID), of which 78 duplicates were removed. After the title and abstract screening of
164 the remaining 486 studies, we removed 461 studies that did not meet the eligibility criteria. A
165 full-text screening of the remaining 25 studies was performed by two team members (MNN and
166 HSA), from which we further excluded 13 articles. Of these 13 excluded studies, 10 studies were
167 conducted with population groups other than patients and the general public, 2 studies were
168 non-empirical, and 1 study was not focused on perceptions of ILP.

169 The eligible studies were published between 2006 and 2022, from the USA (7), Australia
 170 (1), Lebanon (1), Malaysia (1), Pakistan (1), South Africa (1) and Turkey (1). In 12 studies,
 171 quantitative methods were used, while only 1 study had a qualitative research design. Ten
 172 studies were conducted with patients, while 4 studies were carried out with the general public.
 173 (10, 19-21) The sample size in quantitative studies ranged from 192 to 3852 participants,
 174 whereas the qualitative study was conducted with 50 participants. In quantitative studies, a
 175 total of 4965 (51%) females and 4802 (49%) males participated, whereas the qualitative study
 176 was conducted with 28 female and 22 male participants. The age of the participants across all
 177 studies ranged from 18-70 years old. A detailed description of the characteristics of the eligible
 178 studies is given in Table 1.

Study	Approach	Aims	Country	Population	Sample	Key findings
Semin et al. (2006)	Quantitative	To investigate the patients' opinions on the promotional activities of pharmaceutical companies.	Turkey	Patients	584	<ol style="list-style-type: none"> 1. Patients had a great awareness of pharmaceutical incentivisation to physicians. 2. Patients thought pharmaceutical incentivisation to physicians is an unethical practice. 3. Patients believed pharmaceutical incentivisation can affect physicians' prescribing behaviour.
Goff et al. (2008)	Qualitative	To explore patients' beliefs and preferences about medication prescribing to understand factors that might affect medication adherence.	USA	Patients	50	<ol style="list-style-type: none"> 1. Patients believed that pharmaceutical companies have a great influence on physicians.

Tattersall et al. (2009)	Quantitative	To seek the views of patients attending general practice about doctors' interactions with the pharmaceutical industry and their wishes for disclosure of this information.	Australia	Patients	906	<ol style="list-style-type: none"> 1. Patients had a patchy knowledge about incentive-linked prescribing. 2. Patients wanted to know if their doctor obtained any benefits in cash or kind from the pharmaceutical industry. 3. Physicians' disclosure of competing interests is important to help patients make informed treatment decisions.
Jastifer et al. (2009)	Quantitative	To examine the general public's attitudes toward and awareness of physicians' acceptance of gifts from the pharmaceutical industry.	USA	Patients	903	<ol style="list-style-type: none"> 1. Participants reported various incentive types given to physicians from pharmaceutical companies such as drug samples, ballpoint pens, books, meals, and sponsorships for travel. 2. A majority of participants disapproved of gifts of a higher value such as travel sponsorships.
Crigger et al. (2009)	Quantitative	To explore public perceptions of health care providers' role in pharmaceutical marketing.	USA	General Public	223	<ol style="list-style-type: none"> 1. Participants believed that their healthcare providers' prescribing practices were influenced by pharmaceutical representatives. 2. Participants were supportive of gifts for educational purposes.
Grande et al. (2012)	Quantitative	To measure patient perceptions about the prevalence of industry gifts and their relationship to trust in doctors and the health care system.	USA	Patients	2029	<ol style="list-style-type: none"> 1. 34% of the participants believe almost all doctors receive gifts. 2. Participants of higher socioeconomic status (income, education) and younger age were more likely to believe their physician receives gifts. 3. Participants who believed their physician received gifts were more likely to report low trust in physicians.

Green et al. (2012)	Quantitative	To explore patients' awareness of interactions between physicians and the pharmaceutical industry and to examine whether those interactions impact trust and the doctor-patient relationship.	USA	Patients	192	<ol style="list-style-type: none"> 1. A majority of patients were unaware of the financial relationship between pharmaceutical companies and physicians. 2. Patients reported having less trust in physicians who accepted gifts from pharmaceutical companies. 3. Some patients reported that they would be less likely to take a prescribed medication if their physician had recently accepted gifts.
Wise et al. (2013)	Quantitative	To examine patients' perceptions of the practice of physicians accepting gifts from the pharmaceutical industry.	South Africa	Patients	200	<ol style="list-style-type: none"> 1. Patients felt that it was unacceptable for physicians to accept a gift from a pharmaceutical Company. 2. A majority of patients believed that doctors were influenced by accepting gifts. 3. A majority of patients preferred to be cared for by a doctor who had no relationship with or did not accept gifts from, pharmaceutical companies.
Perry et al. (2014)	Mixed methods	To explore how patients perceive payments made by drug and device companies to physicians.	USA	Patients	881	<ol style="list-style-type: none"> 1. Payments had a significant effect on patients' trust in physicians. 2. Patients were less likely to identify ethical conflict if they perceived themselves as potential beneficiaries of the free drug samples.
Ammous et al. (2017)	Quantitative	To assess the awareness and attitudes of the general public in Lebanon regarding the interactions between physicians and pharmaceutical companies.	Lebanon	General Public	263	<ol style="list-style-type: none"> 1. A majority of patients were aware of pharmaceutical company presence in physicians' offices. 2. A smaller percentage of participants were aware of the gift-related practices of physicians. 3. Patients' level of trust was affected if physicians accepted gifts of a higher value from pharmaceutical companies.

Hwong et al. (2017)	Quantitative	To assess how viewing online public disclosure of industry payments affects patients' trust ratings for physicians, the medical profession, and the pharmaceutical and medical device industry.	USA	General Public	278	<ol style="list-style-type: none"> 1. Physicians who received payments received lower ratings for honesty and fidelity as compared to physicians who received no payments. 2. The disclosure website did not affect trust ratings for the medical profession or industry.
Gillani et al. (2022)	Quantitative	To explore patient perceptions and attitudes regarding physician–pharmaceutical company interactions.	Pakistan	Patients	3852	<ol style="list-style-type: none"> 1. A large number of patients were aware of physician–pharmaceutical company interactions. 2. A small number of participants were aware of the financial relationship between physicians and pharmaceutical companies.
Kaur et al. (2022)	Quantitative	To explore the Malaysian public's perceptions towards these relationships between physicians and the medical manufacturing industry.	Malaysia	General Public	361	<ol style="list-style-type: none"> 1. More than half of the participants were aware of the relationships between physicians and the pharmaceutical industry. 2. Online platforms were believed to be the preferred ways for physicians' disclosure of financial ties with the pharmaceutical industry.

179

180 Guided by our research questions, we explored three major themes identified in the
181 review of eligible studies. The first theme was about HCCs' understanding of pharmaceutical
182 incentivisation to physicians. Here, we organised information regarding the extent to which
183 HCCs were aware of the types of incentives that pharmaceutical companies typically provided
184 to physicians, the mechanism through which incentivisation happened, and factors associated
185 with the level of HCCs' awareness about pharmaceutical incentivisation to physicians. The
186 second theme contains information about HCCs' perceptions of the risks associated with
187 physicians' engagement in ILP. The third theme synthesised information about HCCs' proposed

188 actions for policy and regulation required to address pharmaceutical incentivisation to
189 physicians. An outline of these interrelated themes is given in Figure 2.

190 **Figure 2 Caption: Illustration of HCCs' perceptions of pharmaceutical incentivisation to**
191 **physicians**

192 ***Theme 1: Understanding of pharmaceutical incentivisation***

193 The level of HCCs' awareness about pharmaceutical incentivisation to physicians was assessed
194 in 9 studies. Six studies conducted in the USA, Lebanon, Pakistan, Malaysia, and Turkey, showed
195 a greater HCC awareness of pharmaceutical incentivisation to physicians (10, 19, 20, 22-25). For
196 instance, in a study in the USA, 55% of the participants believed that their physicians receive
197 gifts from pharmaceutical companies, whereas 34% thought all physicians do so. (22) Studies
198 from Pakistan and Lebanon reported that more than half of the participants (Pakistan: 50.1%;
199 Lebanon: 53%) witnessed items with pharmaceutical company logos on them in physicians'
200 offices. One study in Australia, however, showed a low awareness among participants regarding
201 pharmaceutical incentivisation. In this study, 76% of the participants were unaware of any
202 financial relationship between physicians and pharmaceutical companies, and 84% of them
203 believed that physicians' disclosure of their financial engagement with pharmaceutical
204 companies would help patients make informed treatment decisions. (26)

205 The types of incentives that pharmaceutical companies typically provide to physicians
206 were mentioned by HCCs in 5 studies (10, 19, 20, 24, 25). For example, in Ammous et al's study
207 in Lebanon, a majority of participants did not know whether their physicians take any
208 incentives/benefits from pharmaceutical companies, although 44% of them believed gifts might
209 influence their physicians' prescribing behaviour. (10) In Pakistan, HCCs believed physicians

210 take a range of incentives/benefits from pharmaceutical companies such as items valued at
211 USD 90 or more (16.8%), participation in social activities organised by pharmaceutical
212 companies (30.1%), paid trips (13.3%), meals (20%), and notepads/pens (49.9%). (24) In
213 Malaysia, HCCs pointed to free drug samples, educational materials, and the ownership of
214 company stocks as other pharmaceutical incentives given to physicians. (20) In two US-based
215 studies, HCCs spoke about the incentives they believed were acceptable or unacceptable for
216 physicians to take from pharmaceutical companies (22, 27). Most of the HCCs in these studies
217 approved of incentives of lesser value such as ball-point pens and free drug samples. The
218 acceptability of these items was attributed to the idea that HCCs might view pens as trivial and
219 unable to influence physicians' prescribing behaviour, whereas free drug samples might be
220 viewed as a benefit to patients. Also, in Pakistan, lecturing or researching for pharmaceutical
221 companies in exchange for money was considered acceptable, for over half of the participants
222 (53.3%). (24)

223 In most of the studies, HCCs doubted the professionalism of physicians who accepted
224 incentives from pharmaceutical companies, as this practice was perceived against the
225 professional ethics in medical practice. (10, 19, 20, 23, 24, 28, 29) In the US, HCCs perceived
226 physicians who had financial ties with pharmaceutical companies as dishonest, and hence not
227 working in the best interests of HCCs. (21)

228 ***Theme 2: Perceptions of hazards linked to incentivisation***

229 The perception of the influence of pharmaceutical incentivisation on physicians' prescribing
230 behaviour was noted in nine studies. (10, 19, 20, 23, 24, 26-29). Even gifts of lesser value were
231 believed to distort physicians' prescribing behaviour in Pakistan and Lebanon, (10, 24) leading

232 patients to consider prescriptions less reliable. (23) Therefore, in the case where a smaller
233 number of HCCs were aware, they wanted to know if their physicians had financial ties with
234 pharmaceutical companies. (26) Nevertheless, in some studies, a smaller number of HCCs
235 reported a lower trust in their physicians, even though they thought incentivisation could
236 influence their prescribing behaviours. (10, 20, 24). One of the reasons explained in those
237 studies was that HCCs might find the relationship between physicians and pharmaceutical
238 companies from the perspective of knowledge exchange. (10, 24). However, differences in the
239 level of trust were noted with respect to HCCs' level of knowledge, race, and ethnicity. (20, 26)
240 Although physicians' disclosure of receiving payments from pharmaceutical companies might
241 influence perceptions of honesty and professionalism, higher payments negatively affected
242 their trust in physicians. (21, 25, 29) In some studies, HCCs believed that physicians who receive
243 incentives from pharmaceutical companies could prioritise pharmaceutical company
244 representatives over HCCs. This practice could further add to HCCs' problems, as they
245 experience a longer waiting time while physicians interact with pharmaceutical company
246 representatives. (10, 19, 20, 23, 24, 28, 30)

247 ***Theme 3: HCCs' suggestions for policy and practice***

248 HCCs demanded transparency regarding physicians' financial ties with pharmaceutical
249 companies, so they could maintain their trust in physicians. (20, 26, 30) HCCs also put a strong
250 emphasis on better regulatory controls, so the relationship between physicians and
251 pharmaceutical companies became transparent, which could increase their trust in healthcare
252 systems. (10, 20, 23) The suggestions about public awareness campaigns regarding
253 pharmaceutical incentivisation were also noted in a few studies, as HCCs believed better

254 communication with physicians was contingent on better awareness about healthcare systems.
255 (10, 20) Furthermore, HCCs thought physicians needed to work in the best interests of HCCs
256 and ensure to self-regulate their interactions with pharmaceutical companies. (10, 29) In one
257 study, HCCs believed that it was highly necessary for physicians to clearly communicate
258 information about the medications they prescribe because doing so could create a sense of
259 professionalism, empathy, and trust. (30)

260 **Discussion**

261 In this review, we grouped HCCs' perceptions into three broader categories: understanding of
262 pharmaceutical incentivisation of physicians, perceptions of risks linked to ILP, and suggestions
263 to improve the transparency of physicians. Our synthesis of the existing research has several
264 important messages. First, HCCs had a mixture of good and patchy knowledge about the
265 pharmaceutical incentivisation of physicians, having important implications for the healthcare
266 system perspective. HCCs' awareness of pharmaceutical incentivisation to physicians leads to
267 several perceptions of hazards linked to it such as distorted prescribing behaviour, growing
268 mistrust in physicians, and a lack of attention paid to patients. In many studies, HCCs believed
269 that when physicians were incentivised, they would aim to meet pharmaceutical sales targets,
270 even if they would need to prescribe medications unnecessarily. (10, 19, 20, 24, 27) The sense
271 of incentive-driven prescriptions can further produce contexts for HCCs to reduce their trust in
272 physicians. There is strong evidence that HCCs who lose trust in physicians are less likely to
273 adhere to medical treatments recommended to them – something that may place a significant
274 morbidity and financial burden on healthcare systems. (31-33) The presence of pharmaceutical
275 sales representatives and promotional items in physicians' offices, while HCCs wait to see their

276 physicians, as explained in Ammous et al.'s (10) study, is one of the ways that may contribute to
277 HCCs' awareness of pharmaceutical incentivisation. Hence, trust is a basic element of a healthy
278 and respectful relationship between physicians and patients. Even if patients are reasonably
279 health literate, they rely on physicians who are experts in the field of medicine. (34) The
280 reduction in HCCs' trust is a clear sign of how the acceptance of pharmaceutical incentives can
281 affect physicians' reputations in society. Therefore, HCCs in many studies expressed their
282 interest in knowing whether their physicians had any financial ties with pharmaceutical
283 companies, as the non-disclosure might be taken as an injustice.

284 Second, we also found that HCCs in most of the studies were reasonably aware of the
285 mechanisms through which pharmaceutical incentivisation takes place and the types of
286 incentives that physicians typically receive from pharmaceutical companies. This finding is
287 consistent with several empirical studies with physicians, pharmaceutical companies, and other
288 relevant stakeholders who testify to the unethical exchanges between physicians and
289 pharmaceutical companies in various parts of the world. (4, 8, 13, 35, 36) This means that even
290 though physicians and pharmaceutical companies may attempt to establish financial ties
291 discretely, HCCs have a reasonable awareness of this practice.

292 Third, the acceptance of incentives from pharmaceutical companies was also deemed
293 against professional medical ethics. This has implications for not only developing clear-cut
294 guidelines on the ethics of dealing with pharmaceutical companies but also ensuring that
295 physicians can fully understand and follow them. In many LMICs, such as Pakistan, no clear
296 guidelines on professional medical ethics exist, and physicians often find it difficult to
297 determine ethical boundaries when they interact with pharmaceutical sales representatives

298 who visit them to promote drugs. (7) Therefore, the development of guidelines on ethics should
299 be the prime responsibility of states to help physicians recognise potential conflicts of interest
300 while dealing with physicians.

301 Fourth, a few studies also showed that HCCs maintained their trust if their physicians
302 accepted incentives of lesser value or small payments in exchange for lecturing or researching
303 for pharmaceutical companies. This means that HCCs are aware of the importance of the
304 interaction between the pharmaceutical industry and physicians, which happens around
305 knowledge exchange and scientific development.

306 We limited our search to English-language scholarly journal articles indexed in the
307 databases like Scopus, Medline (OVID), EMBASE (OVID), and a search of Google Scholar. The
308 extension of the search to include research in other languages, and the inclusion of grey
309 literature could help to discover more information. Studies that we included in the review
310 varied in terms of settings and methods, which we analysed to present a general landscape of
311 the published literature on HCCs' perceptions of pharmaceutical incentivisation to physicians. A
312 full systematic review would provide a more rigorous analysis of the studies.

313 Our review has several implications for future research. One of our major findings is that
314 most of the empirical studies conducted with HCCs are underpinned by a positivist approach.
315 Quantitative methods were useful in that they helped researchers to determine the distribution
316 of the sampled HCCs about their beliefs and knowledge about pharmaceutical incentivisation
317 and how their beliefs/knowledge might affect their attitudes toward physicians. However,
318 qualitative research can prove more useful in explaining social conditions and contexts linked to
319 HCCs' perceptions, which can further provide rich insights for policy and practice. More than

320 half of the studies in our review came from high-income countries such as the USA and
321 Australia. The problem of pharmaceutical incentivisation is more critical in LMICs due to weak
322 regulatory controls. More future studies in LMICs are required for a better understanding of the
323 dynamics of pharmaceutical incentivisation to physicians, so appropriate interventions are
324 developed to address this problem.

325 **Conclusion**

326 HCCs in different parts of the world seem to be reasonably aware of the unethical financial
327 relationship that is sometimes established between physicians and pharmaceutical companies.
328 It is therefore necessary for physicians to avoid engaging in ILP. In the case where physicians'
329 professional services are required in the pharmaceutical industry, they must publicly disclose
330 this, so their patients maintain trust. The deterioration of trust due to physicians' engagement
331 in ILP can not only reduce their adherence to treatments recommended by physicians but also
332 negatively affect physicians' reputations in society. Finally, we emphasise the importance of
333 health system research representing HCCs' voices to shape and strengthen policy, regulation,
334 and practice.

335 **Funding information**

336 This work is supported by the UK Research and Innovation (UKRI) under grant number
337 MR/T02349X/1.

338 **Conflict of interest**

339 The corresponding author is also part of the editorial board of PLOS Global Public Health.


340 **References**

341 1. Chen M, Kadetz P, Cabral C, Lambert H. Prescribing antibiotics in rural China: the influence of
342 capital on clinical realities. *Frontiers in sociology*. 2020;5:66.

- 343 2. Davari M, Khorasani E, Tigabu BM. Factors influencing prescribing decisions of physicians: a
344 review. *Ethiopian journal of health sciences*. 2018;28(6).
- 345 3. Khazzaka M. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in
346 Lebanon: ethics, gifts, and samples. *BMC health services research*. 2019;19(1):1-11.
- 347 4. Noor MN, Liverani M, Bryant J, Rahman-Shepherd A, Sharif S, Aftab W, et al. The healthcare field
348 as a marketplace: general practitioners, pharmaceutical companies, and profit-led prescribing in
349 Pakistan. *Health Sociology Review*. 2022:1-15.
- 350 5. Morel CM, Lindahl O, Harbarth S, de Kraker ME, Edwards S, Hollis A. Industry incentives and
351 antibiotic resistance: an introduction to the antibiotic susceptibility bonus. *The Journal of Antibiotics*.
352 2020;73(7):421-8.
- 353 6. Stacherl B, Renner A-T, Weber D. Financial incentives and antibiotic prescribing patterns:
354 Evidence from dispensing physicians in a public healthcare system. *Social Science & Medicine*.
355 2023:115791.
- 356 7. Khan M, Rahman-Shepherd A, Noor MN, Sharif S, Hamid M, Aftab W, et al. Incentivisation
357 practices and their influence on physicians' prescriptions: A qualitative analysis of practice and policy in
358 Pakistan. *PLOS global public health*. 2023;3(6):e0001890.
- 359 8. Noor MN, Rahman-Shepherd A, Siddiqui AR, Aftab W, Shakoor S, Hasan R, et al. Socioecological
360 factors linked with pharmaceutical incentive-driven prescribing in Pakistan. *BMJ Global Health*.
361 2023;6(Suppl 3):e010853.
- 362 9. Blendon RJ, Benson JM, Hero JO. Public trust in physicians—US medicine in international
363 perspective. *N Engl J Med*. 2014;371(17):1570-2.
- 364 10. Ammous A, Eddine SBZ, Dani A, Dbaibou J, El-Asmar JM, Sadder L, et al. Awareness and attitudes
365 of the Lebanese population with regard to physician–pharmaceutical company interaction: a survey
366 study. *BMJ open*. 2017;7(3):e013041.
- 367 11. Fadare JO, Oshikoya KA, Ogunleye OO, Desalu OO, Ferrario A, Enwere OO, et al. Drug
368 promotional activities in Nigeria: impact on the prescribing patterns and practices of medical
369 practitioners and the implications. *Hospital practice*. 2018;46(2):77-87.
- 370 12. Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical
371 industry generally and sales representatives specifically and their association with physicians' attitudes
372 and prescribing habits: a systematic review. *BMJ open*. 2017;7(9):e016408.
- 373 13. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts
374 from pharmaceutical companies to French general practitioners and their drug prescribing patterns in
375 2016: retrospective study using the French Transparency in Healthcare and National Health Data System
376 databases. *Bmj*. 2019;367.
- 377 14. Fadlallah R, Nas H, Naamani D, El-Jardali F, Hammoura I, Al-Khaled L, et al. Knowledge, beliefs
378 and attitudes of patients and the general public towards the interactions of physicians with the
379 pharmaceutical and the device industry: a systematic review. *PLoS One*. 2016;11(8):e0160540.
- 380 15. Noor MN. Healthcare Consumers' Perceptions of Incentive-Linked Prescribing: A Scoping Review
381 of Research OSF Registries2024 [Available from: <https://osf.io/9y7zj>].
- 382 16. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International*
383 *journal of social research methodology*. 2005;8(1):19-32.
- 384 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for
385 scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine*. 2018;169(7):467-
386 73.
- 387 18. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia 2023
388 [Available from: <https://support.covidence.org/help/how-can-i-cite-covidence>].
- 389 19. Crigger NJ, Courter L, Hayes K, Shepherd K. Public perceptions of health care professionals'
390 participation in pharmaceutical marketing. *Nursing Ethics*. 2009;16(5):647-58.

- 391 20. Kaur A, Singh S, Ng D, Pok W. Physician–Medical Manufacturing Industry Relationships:
392 Perceptions of Malaysians. *Journal of Health Management*. 2022;24(4):662-9.
- 393 21. Hwong AR, Sah S, Lehmann LS. The effects of public disclosure of industry payments to
394 physicians on patient trust: a randomized experiment. *Journal of General Internal Medicine*.
395 2017;32:1186-92.
- 396 22. Grande D, Shea JA, Armstrong K. Pharmaceutical industry gifts to physicians: patient beliefs and
397 trust in physicians and the health care system. *Journal of general internal medicine*. 2012;27:274-9.
- 398 23. Semin S, Güldal D, Özçakar N, Mevsim V. What patients think about promotional activities of
399 pharmaceutical companies in Turkey. *Pharmacy World and Science*. 2006;28:199-206.
- 400 24. Gillani AH, Omer S, Arshad H, Liu W, Chen C, Bashir S, et al. Awareness and Attitudes of the
401 Pakistani Population With Regard to Physician–Pharmaceutical Company Interaction: A Cross-Sectional
402 Study. *Frontiers in Pharmacology*. 2022;12:787891.
- 403 25. Perry JE, Cox D, Cox AD. Trust and transparency: patient perceptions of physicians' financial
404 relationships with pharmaceutical companies. *Journal of Law, Medicine & Ethics*. 2014;42(4):475-91.
- 405 26. Tattersall MH, Dimoska A, Gan K. Patients expect transparency in doctors' relationships with the
406 pharmaceutical industry. *Medical Journal of Australia*. 2009;190(2):65-8.
- 407 27. Jastifer J, Roberts S. Patients' awareness of and attitudes toward gifts from pharmaceutical
408 companies to physicians. *International Journal of Health Services*. 2009;39(2):405-14.
- 409 28. Green MJ, Masters R, James B, Simmons B, Lehman E. Do gifts from the pharmaceutical industry
410 affect trust in physicians? *Family medicine*. 2012;44(5):325-31.
- 411 29. Wise R, Rodseth RN. The opinion of patients at a local South Africa teaching hospital on
412 physician-industry relations. *Southern African Journal of Anaesthesia and Analgesia*. 2013;19(3):160-3.
- 413 30. Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding
414 doctors' medication recommendations. *Journal of general internal medicine*. 2008;23:236-41.
- 415 31. Sanford K, Clifton M. The Medical Mistrust Multiformat Scale: Links with vaccine hesitancy,
416 treatment adherence, and patient–physician relationships. *Psychological Assessment*. 2022;34(1):10.
- 417 32. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and
418 consequences. *The American journal of the medical sciences*. 2016;351(4):387-99.
- 419 33. Abel WM, Efird JT. The association between trust in health care providers and medication
420 adherence among Black women with hypertension. *Frontiers in public health*. 2013;1:66.
- 421 34. Kao AC, Green DC, Davis NA, Koplan JP, Cleary PD. Patients' trust in their physicians: effects of
422 choice, continuity, and payment method. *Journal of general internal medicine*. 1998;13(10):681-6.
- 423 35. Bennett J, Collins J. The relationship between physicians and the biomedical industries: advice
424 from the Royal College of Physicians. *Clinical medicine (London, England)*. 2002;2(4):320-2.
- 425 36. Holden ACL, Spallek H. Looking Gift-horses in the Mouth: Gift-giving, Incentives and Conflict of
426 Interest in the Dental Profession. *Journal of law and medicine*. 2018;25(3):794-9.

427



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.27.24303447>; this version posted February 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1



Perceptions of incentivisation

- The interaction between physicians and pharmaceutical companies.
- Incentive types accepted by physicians.
- The unethical dimension of pharmaceutical incentivisation.



Perceptions of hazards linked to incentivisation

- The prescribing of unnecessary medications.
- The prioritisation of pharmaceutical representatives over patients in terms of time and attention.
- Growing mistrust in incentivised physicians.



Suggestions

- Physicians' public disclosure of financial ties with pharmaceutical companies.
- Physicians' self-regulation
- Strong health systems regulations
- Physicians' better communication with patients

Figure 2